Trial reportWorld journal of urology2021
Escherichia coli Nissle 1917 as adjuvant therapy in patients with chronic bacterial prostatitis: a non-blinded, randomized, controlled trial.
Trial report in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Targeting the brain-gut-prostate axis in chronic prostatitis: mechanisms and therapeutics.Frontiers in endocrinology · 2025Pooled it
- D-Mannose PlusMedicina (Kaunas, Lithuania) · 2023Trial
- Subacute 28-Day OECD-Guided Oral Toxicity Study ofJournal of microbiology and biotechnology · 2026Article
- Unraveling the microbial landscape in prostate cancer: pathogenesis to therapy.NPJ biofilms and microbiomes · 2026Review
- Role of microbiota in pain: From bench to bedside.iMetaOmics · 2025Review
- Analysis of the Beneficial Effects of Probiotics on the Gut-Prostate Axis Using Prostatic Co-Culture Model.Foods (Basel, Switzerland) · 2024Article
- Review
- The Efficacy of FlogofilmJournal of clinical medicine · 2023Article
- Transcutaneous electrical nerve stimulation combined with levofloxacin and tamsulosin for patients with chronic prostatitis: clinical efficacy and changes in serum factors.American journal of translational research · 2023Article
- Potential role of gut microbiota in prostate cancer: immunity, metabolites, pathways of action?Frontiers in oncology · 2023Review
- Article
- Oral Preparation of Hyaluronic Acid, Chondroitin Sulfate, Curcumin, and Quercetin (IalurilPathophysiology : the official journal of the International Society for Pathophysiology · 2022Article
- The Role of Microbial Factors in Prostate Cancer Development-An Up-to-Date Review.Journal of clinical medicine · 2021Review
- Probiotics to treat chronic bacterial prostatitis.Nature reviews. Urology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy and safety of Escherichia coli Nissle 1917 (EcN) in association with levofloxacin in patients with chronic bacterial prostatitis (CBP).
methodsPatients with CBP referred to our clinic from September 2017 to July 2019 were enrolled. At baseline, the symptomatology was assessed with the NIH-Chronic Prostatitis Symptom Index (NIH-CPSI), while the Meares-Stamey test was used to diagnose the infection. Patients were randomized (1:1) in two groups (A and B). All subjects underwent oral administration of Levoxacin® 500 mg once daily for 4 weeks. Only the patients in Group B underwent oral administration of EcN® 320 mg, twice daily for 4 weeks and then once daily for 8 weeks. After 3 months, each patient repeated the NIH-CPSI questionnaire, while the Meares-Stamey test was repeated at 3 and 6 months in patients who reported persistent symptoms. All adverse events (AEs) were recorded.
resultsA total of 110 patients were enrolled. After 3 months patients in Group B reported a significantly lower NIH-CPSI score (5.85 ± 3.07 vs. 7.64 ± 3.86; p = 0.009) and biological recurrences rate (9.8 vs. 26.9%; p = 0.043). At 6 months the biological recurrences rate was significantly lower in Group B (8.7 vs. 28.9%; p = 0.038). Only three patients in Group A and six in Group B (p = 0.25) complained mild AEs.
conclusionsCombination therapy with EcN and levofloxacin allows a better control of symptoms and biological recurrences in patients with CBP, without worsening the safety of the treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.